Outputs (3)

Rapid genotyping of Toxoplasma gondii isolates via Nanopore-based multi-locus sequencing (2024)
Journal Article
Koutsogiannis, Z., & Denny, P. W. (2024). Rapid genotyping of Toxoplasma gondii isolates via Nanopore-based multi-locus sequencing. AMB Express, 14(1), Article 68. https://doi.org/10.1186/s13568-024-01728-x

Toxoplasma gondii is an obligate intracellular parasite associated with severe disease, especially in the immunosuppressed. It is also a cause of congenital malformation and abortion in both animals and humans and is considered one of the most import... Read More about Rapid genotyping of Toxoplasma gondii isolates via Nanopore-based multi-locus sequencing.

TREATMENT OF LEISHMANIASIS (2024)
Patent
Denny, P., Steel, P., & Lyne, V. (2024). TREATMENT OF LEISHMANIASIS. WO 2024/084186 A1

The invention relates to compounds of formula (I), which may be used in the treatment of microbial infections. In particular, compounds of formula (I) are effective at treating leishmaniasis. The invention extends to novel compositions, therapies and... Read More about TREATMENT OF LEISHMANIASIS.

Clemastine/tamoxifen hybrids as easily accessible antileishmanial drug leads (2024)
Journal Article
Agostino, V. S., Buerdsell, M. L., Uliana, S. R. B., Denny, P. W., Coelho, A. C., & Steel, P. G. (2024). Clemastine/tamoxifen hybrids as easily accessible antileishmanial drug leads. Organic and Biomolecular Chemistry, 22(9), 1812-1820. https://doi.org/10.1039/d3ob02091f

A library of hybrid molecules is developed based on the common chemical features shared by clemastine and tamoxifen both of which are well known for their antileishmanial activities. In the initial screening against Leishmania major and L. amazonensi... Read More about Clemastine/tamoxifen hybrids as easily accessible antileishmanial drug leads.